Key points from article :
OneSkin launched a cosmetic product claimed to reduce levels of senescent cells in aged skin.
The product contains a peptide 14 (OS-01) and decapeptide-52.
The use of OS-01 is similar to topical application of rapamycin.
Though no direct destruction occurs but a reduction in senescent cell creation and activity is seen.
This allows existing processes of senescent cell clearance to catch up in aged skin.
OS-01 performs better than rapamycin in reducing markers of cellular senescence.
Formal trials and resulting human data are pending - though the product is available for anyone who wants to give it a try.
Peptide 14 decreased human dermal fibroblasts (HDF) senescence induced by Hutchinson-Gilford Progeria (HGPS), chronological ageing, UV-B radiation, etc.
It promoted skin health, reduced senescent cell markers and biological age of samples.
It outperformed retinol treatment, the current gold-standard in "anti-aging" skin care.
Research by OneSkin published in Biorxiv.
